{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-25-000030","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.650655+00:00","generated_at":"2026-05-26T01:29:54.501658+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M","bullets":["Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).","Net income $18.2M (incl. $50.3M stock comp) vs net loss $57.5M in 2023.","Adjusted EBITDA $75.0M vs -$4.4M in 2023; cash $293.1M, up $50M.","TissueCypher Barrett's Esophagus test reports surged 130% to 20,956; dermatology reports up 17%.","2025 revenue guidance $280-295M, below 2024 actual but achieved prior 2025 target a year early."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-25-000030","json":"https://secwatch.observer/filing/0001447362-25-000030.json","markdown":"https://secwatch.observer/filing/0001447362-25-000030.md","text":"https://secwatch.observer/filing/0001447362-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736225000030/0001447362-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736225000030/cstl-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:29:54.501658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}